EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY-NC 4.0

A gene risk score using missense variants in SLCO1B1 is associated with earlier onset statin intolerance

Margherita Bigossi iD, Cyrielle Maroteau iD, Adem Y Dawed iD, Alasdair Taylor, Sundararajan Srinivasan, Alaa' Lufti Melhem iD, Ewan R Pearson iD, Roberto Pola iD, Colin N A Palmer iD, Moneeza K Siddiqui iD

European Heart Journal - Cardiovascular Pharmacotherapy · 2023

DOI: 10.1093/ehjcvp/pvad040 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift European Heart Journal - Cardiovascular Pharmacotherapy, 2023. Verfasst von Margherita Bigossi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pat McPherson Centre for Pharmacogenetics & Pharmacogenomics, Division of Population Health & Genomics, School of Medicine, Ninewells Hospital & Medi…. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Muscular Diseases. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Wellcome Trust, Department of Health, Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aims The efficacy of statin therapy is hindered by intolerance to the therapy, leading to discontinuation. Variants in SLCO1B1, which encodes the hepatic transporter OATB1B1, influence statin pharmacokinetics, resulting in altered plasma concentrations of the drug and its metabolites. Current pharmacogenetic guidelines require sequencing of the SLCO1B1 gene, which is more expensive and less accessible than genotyping. In this study, we aimed to develop an easy, clinically implementable functional gene risk score (GRS) of common variants in SLCO1B1 to identify patients at risk of statin intolerance. Methods and results A GRS was developed from four common variants in SLCO1B1. In statin users from Tayside, Scotland, UK, those with a high-risk GRS had increased odds across three phenotypes of statin intolerance [general statin intolerance (GSI): ORGSI 2.42; 95% confidence interval (CI): 1.29–4.31, P = 0.003; statin-related myopathy: ORSRM 2.51; 95% CI: 1.28–4.53, P = 0.004; statin-related suspected rhabdomyolysis: ORSRSR 2.85; 95% CI: 1.03–6.65, P = 0.02]. In contrast, using the Val174Ala genotype alone or the recommended OATP1B1 functional phenotypes produced weaker and less reliable results. A meta-analysis with results from adjudicated cases of statin-induced myopathy in the PREDICTION-ADR Consortium confirmed these findings (ORVal174Ala 1.99; 95% CI: 1.01–3.95, P = 0.048; ORGRS 1.76; 95% CI: 1.16–2.69, P = 0.008). For those requiring high-dose statin therapy, the high-risk GRS was more consistently associated with the time to onset of statin intolerance amongst the three phenotypes compared with Val174Ala (GSI: HRVal174Ala 2.49; 95% CI: 1.09–5.68, P = 0.03; HRGRS 2.44; 95% CI: 1.46–4.08, P < 0.001). Finally, sequence kernel association testing confirmed that rare variants in SLCO1B1 are associated with the risk of intolerance (P = 0.02). Conclusion We provide evidence that a GRS based on four common SLCO1B1 variants provides an easily implemented genetic tool that is more reliable than the current recommended practice in estimating the risk and predicting early-onset statin intolerance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsMuscular DiseasesHumansGenotypeLiver-Specific Organic Anion Transporter 1PhenotypeRisk Factors

Stichwörter der Autor:innen

SLCO1B1Adverse drug reactionsMusculoskeletal symptomsPharmacogenomicsPrecision medicineStatins

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsLiver-Specific Organic Anion Transporter 1SLCO1B1 protein, human

Autor:innen und Institutionen

  • Pat McPherson Centre for Pharmacogenetics & Pharmacogenomics, Division of Population Health & Genomics, School of Medicine, Ninewells Hospital & Medical School, University of Dundee, DundeeDD1 9SY, UK.
  • Section of Internal Medicine and Thromboembolic Diseases, Department of Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, L.go A. Gemelli 8, 00168 Rome, Italy.
  • Human Genetics Centre of Excellence, Novo Nordisk Research Centre Oxford, Oxford OX3 7FZ, UK.

ORCID-Profile: Margherita Bigossi, Cyrielle Maroteau, Adem Y Dawed, Alaa' Lufti Melhem, Ewan R Pearson, Roberto Pola, Colin N A Palmer, Moneeza K Siddiqui

Förderung

  • Wellcome Trust
  • Department of Health
  • Medical Research Council
  • National Institute for Health Research
  • UK Medical Research Council
  • EC Seventh Framework Programm

Zitieren

APA

Bigossi, M., Maroteau, C., Dawed, A. Y., Taylor, A., Srinivasan, S., Melhem, A. L., Pearson, E. R., Pola, R., Palmer, C. N. A., & Siddiqui, M. K. (2023). A gene risk score using missense variants in SLCO1B1 is associated with earlier onset statin intolerance. European Heart Journal - Cardiovascular Pharmacotherapy. https://doi.org/10.1093/ehjcvp/pvad040

Vancouver

Bigossi M, Maroteau C, Dawed AY, Taylor A, Srinivasan S, Melhem AL, et al. A gene risk score using missense variants in SLCO1B1 is associated with earlier onset statin intolerance. European Heart Journal - Cardiovascular Pharmacotherapy. 2023. doi:10.1093/ehjcvp/pvad040

BibTeX
@article{Bigossi2023,
  author = {Bigossi, Margherita and Maroteau, Cyrielle and Dawed, Adem Y and Taylor, Alasdair and Srinivasan, Sundararajan and Melhem, Alaa' Lufti and Pearson, Ewan R and Pola, Roberto and Palmer, Colin N A and Siddiqui, Moneeza K},
  title = {A gene risk score using missense variants in SLCO1B1 is associated with earlier onset statin intolerance},
  journal = {European Heart Journal - Cardiovascular Pharmacotherapy},
  year = {2023},
  doi = {10.1093/ehjcvp/pvad040}
}
Kostenlos starten →